PD-L1 Antibodies, ELISA Kits, Caspase-3 : ABEOMICS

[abeomicsinc]

ABEOMICS develops Antibodies Caspase-3, B7-H4, Dnmt1, PD-L1, TLR, TCF Stat Reporter Cell Line CTLA4, PD-1 Stable Cell lines, Luciferase Assay Kit, PD-L1 Pre-Coated ELISA Kits, Recombinant Antibodies, Inhibitors, anti-PDL1 Immune Checkpoint Reagents for therapies on cancer

[abeomicsinc]

Cell Based Reporter Assay

Cell-based assays can offer an efficient and valuable means to be used to assess a variety of biochemical and functional effects of a substance in vitro, such as cell division and proliferation, signal transduction cascade, activity of different enzymes and reporter genes, antibody- dependent (ADCC)

Cell-based assays can offer an efficient and valuable means to be used to assess a variety of biochemical and functional effects of a substance in vitro, such as cell division and proliferation, signal transduction cascade, activity of different enzymes and reporter genes, antibody- dependent (ADCC) and complement dependent (CDC) cytoxicity, pathways of programmed cell death, the most concerned cellular phenomena among others.

[abeomicsinc]

Recent advances in treating cancer patients have resulted in the development of biological therapies that can prove to be a promising alternative to conventional cancer therapies. Immuno-therapy harnesses the body's immune system to identify and fight effectively against cancer cells.

[abeomicsinc]

Caspase-3, B7-H4, Dnmt1, PD-L1 Antibodies, TLR, TCF Stat Reporter Cell Line CTLA4, PD-1 Stable Cell lines, Luciferase Assay Kit, PD-L1 Pre-Coated ELISA Kits, Drug Screening Services, Recombinant Antibody, Inhibitors, anti-PDL1 Immune Checkpoint Reagents for therapies on cancer, apoptosis, molecular signaling pathways, genetic and infectious human diseases at Abeomics.com

[abeomicsinc]

ABEOMICS Inc. provides innovative, well validated research reagents to support research in the field of immune oncology. The product line includes Stable cell lines and Reporter cell lines, Antibodies, ELISA kits, Recombinant proteins as well as compound screening services for new drug molecules.

[abeomicsinc]

Cancer Immunotherapy

Recent advances in treating cancer patients have resulted in the development of biological therapies that can prove to be a promising alternative to conventional cancer therapies. Immunotherapy harnesses the body’s immune system to identify and fight effectively against cancer cells. Immunotherapy works by attacking the growth of cancer cells or stimulating the immune system to kill cancer cells. Contradictory to the standard cancer treatment regimes such as chemotherapy, radiation therapy, which act on both normal and cancerous cells, immunotherapeutic treatments are highly specific. A wide range of cancer immunotherapy approaches exists such as immune checkpoint blockers, cancer vaccines, immune-modulators, monoclonal antibodies and cell based immunotherapies have demonstrated to be effective against cancer patients.

The most commonly targeted form of cancer chemotherapy is the use of monoclonal antibodies as they can be tailor-made in the laboratory. They have unique antigen specificity thereby allowing themselves to attach to specific epitopes on cancer cells. This flags the cancer cells and makes it more visible to the immune system so that it can find and destroy those cells. Currently, most of the monoclonal antibodies are undergoing phase 3 clinical trials or awaiting FDA review process. Unlike monoclonal antibodies, non-specific immunotherapy approaches such as administration of immunomodulatory cytokines are also being used to treat melanoma. Cytokines are hormones that are endogenously produced by the body to enhance or suppress T-cell response against cancer cells. IFN-α and IL-2 are most commonly characterized cytokines used in cancer immunotherapy.

The primary cell-based immunotherapy strategy which is successful these days is the use of T-cell therapy, wherein cancer T cells removed from blood are modified with chimeric antigen receptor (CAR) and is then infused back into the patients to treat metastatic cancer. Another form of cell-based immunotherapy used is tumor-infiltrating lymphocytes (TIL) therapy, wherein TIL is surgically removed from tumor tissue and is considerably increased in the laboratory by adding cytokines to it and is then reinfused back into the patient.

A promising treatment that has emerged in recent times for treatment of melanoma is the use of immune checkpoint inhibitors. They act by inhibiting the checkpoint receptors on T cells that act as brakes to the immune system thereby mediating antitumor responses. Some of the commonly used antibody inhibitors that have been commercialized are PD-1, PDL-1, and CTLA-4.

Another more focused approach to cancer immunotherapy is the use of vaccines to encourage the immune system to generate antibodies that can target tumor specific antigens, thereby eradicating cancerous cells. Cancer vaccines include peptide-based, dendritic cell-based, tumor cell-based and DNA cell based. Cancer vaccines can be broadly classified as preventive or therapeutic. Preventive vaccines are commercially available for against cervical and liver cancer causing viruses such as human papillomavirus and hepatitis B virus, respectively.

However, in spite of these advances, limitation such as tumor heterogeneity, unpredictable efficacy and identification of potential markers still exist in the field of cancer immunotherapy. Therefore, new more targeted cancer immunotherapies and preventive strategies are being developed and tested, which will deliver novel efficacious therapy against relapsed or refractory cancer patients.

ABEOMICS Inc. provides innovative, well validated research reagents to support research in the field of immune oncology. The product line includes Stable cell lines and Reporter cell lines, Antibodies, ELISA kits, Recombinant proteins as well as compound screening services for new drug molecules.

[abeomicsinc]

ABEOMICS develops PD1, PD-L1, Recombinant Antibodies, Immuno Check Point Reagents, Reporter Cell lines, Inhibitors, anti-PDL1 reagents for scientific study, production of new diagnostic assays and potential therapies of human diseases with biological interests on cancer, apoptosis, molecular signaling pathways, cellular aging, metabolic disorder, neuro-degenerative, genetic and infectious diseases.